Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546-53. doi:10.1158/2159-8290.CD-13-0353
Gilman SE, Ni MY, Dunn EC, et al. Contributions of the social environment to first-onset and recurrent mania. Mol Psychiatry. 2015;20(3):329-36. doi:10.1038/mp.2014.36
Torres-GarcÃa W, Zheng S, Sivachenko A, et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30(15):2224-6. doi:10.1093/bioinformatics/btu169
Cotlarciuc I, Malik R, Holliday EG, et al. Effect of genetic variants associated with plasma homocysteine levels on stroke risk. Stroke. 2014;45(7):1920-4. doi:10.1161/STROKEAHA.114.005208
Talwalkar A, Liptrap J, Newcomb J, et al. SMaSH: a benchmarking toolkit for human genome variant calling. Bioinformatics. 2014;30(19):2787-95. doi:10.1093/bioinformatics/btu345
Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-77. doi:10.1016/j.ccr.2014.04.024
Ren JG, Seth P, Clish CB, et al. Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. Sci Rep. 2014;4:5414. doi:10.1038/srep05414
Wik E, Trovik J, Kusonmano K, et al. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol Oncol. 2014;134(3):599-606. doi:10.1016/j.ygyno.2014.06.026
Wang Z, Zhu B, Zhang M, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014;23(24):6616-33. doi:10.1093/hmg/ddu363
Okada Y, Kim K, Han B, et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet. 2014;23(25):6916-26. doi:10.1093/hmg/ddu387